Breaking News Instant updates and real-time market news.

EPZM

Epizyme

$16.85

0.6 (3.69%)

11:30
05/17/18
05/17
11:30
05/17/18
11:30

Epizyme's tazemetostat still looks 'approvable and attractive,' says Jefferies

After abstracts were released ahead of the ASCO meeting for new and updated Phase II tazemetostat data in mesothelioma and "more importantly" follicular lymphoma data to be presented at the EHA meeting, Jefferies analyst Michael Yee said the new lymphoma abstract data "looks solid." The high responses rates support Yee's view that tazemetostat looks like "an approval and attractive cancer drug," he tells investors. Yee keeps a Buy rating on Epizyme with a $27 price target.

  • 17

    May

  • 18

    May

EPZM Epizyme
$16.85

0.6 (3.69%)

04/24/18
ROTH
04/24/18
NO CHANGE
Target $24
ROTH
Buy
Epizyme clinical hold temporary, says Roth Capital
Roth Capital analyst Jotin Marango believes Epizyme's partial clinical hold is temporary. While the case of secondary lymphoma raises some doubts on tazemetostat's prospects in front-line, the analyst believes its clinical and commercial value in R/R disease remains intact. Marango reiterates a Buy rating and $24 price target on the shares.
04/24/18
JEFF
04/24/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme shares will bounce back, says Jefferies
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
04/24/18
JMPS
04/24/18
NO CHANGE
Target $28
JMPS
Outperform
Epizyme hold news has 'number of mitigating factors,' says JMP Securities
JMP Securities analyst Michael GKing noted the FDA has issued a partial clinical hold for clinical trials evaluating Epizyme's tazemetostat, but he sees "a number of mitigating factors" to this negative news. Those include the fact that the Phase 2 FL and DLBCL trials are mostly enrolled and that the Phase 2 study in mesothelioma and epithelioid sarcoma are already fully enrolled. He sees it making sense that the FDA would issue a hold "out of an abundance of caution," given the pediatric indication, but he maintains an Outperform rating and $28 price target on Epizyme shares.
04/24/18
RHCO
04/24/18
NO CHANGE
Target $20
RHCO
Buy
Epizyme price target lowered to $20 from $27 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Epizyme to $20, saying that while the FDA hold on the tazemetostat trial should be brief, the 20% decline in the stock price afterhours justifies a more conservative target. In light of the hold, Lawson adds that he is also reducing his probability of success for tazemetostat to 60% from 65% and penetration to 75% from 85% in EZH2 mutant FL, while also reducing the probability of success in INI1-negative solid tumors to 60% from 85% and the penetration to 75% from 85%. The analyst keeps his Buy rating on Epizyme.

TODAY'S FREE FLY STORIES

RDS.A

Royal Dutch Shell

$66.26

0.24 (0.36%)

, RDS.B

Royal Dutch Shell

$68.29

0.13 (0.19%)

09:06
09/20/18
09/20
09:06
09/20/18
09:06
Hot Stocks
Royal Dutch Shell expands relationship with Microsoft »

Royal Dutch Shell (RDS.A,…

RDS.A

Royal Dutch Shell

$66.26

0.24 (0.36%)

RDS.B

Royal Dutch Shell

$68.29

0.13 (0.19%)

MSFT

Microsoft

$111.71

-1.53 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

LRAD

LRAD Corporation

$3.01

-0.015 (-0.50%)

09:04
09/20/18
09/20
09:04
09/20/18
09:04
Hot Stocks
LRAD Corporation announces $2.4M in orders from National Guard, U.S. Military »

LRAD Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$43.85

-0.3 (-0.68%)

09:04
09/20/18
09/20
09:04
09/20/18
09:04
Recommendations
Triumph Bancorp analyst commentary  »

DA Davidson raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

IMAX

Imax

$25.30

0.25 (1.00%)

09:04
09/20/18
09/20
09:04
09/20/18
09:04
Hot Stocks
Imax, Universal Pictures announce multi-year, multi-picture deal »

Universal Pictures and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EDR

EdR

$41.49

(0.00%)

09:02
09/20/18
09/20
09:02
09/20/18
09:02
Hot Stocks
Breaking Hot Stocks news story on EdR »

Education Realty trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSC

Seven Stars Cloud Group

$4.40

0.02 (0.46%)

09:02
09/20/18
09/20
09:02
09/20/18
09:02
Hot Stocks
Ideanomics enters JV with APMEN Trade Tech Co »

Ideanomics is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$39.57

0.48 (1.23%)

09:01
09/20/18
09/20
09:01
09/20/18
09:01
Hot Stocks
FDA schedules Nov. 1 advisory committee to review Alkermes' MDD drug »

The Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

09:00
09/20/18
09/20
09:00
09/20/18
09:00
General news
The 3k initial claims drop »

The 3k initial claims…

09:00
09/20/18
09/20
09:00
09/20/18
09:00
General news
President Trump nominated Nellie Liang to the Federal Reserve Board »

President Trump nominated…

08:59
09/20/18
09/20
08:59
09/20/18
08:59
Conference/Events
The Federal Energy Regulatory Commission to hold a meeting »

Open Commission Meeting…

CCL

Carnival

$66.21

0.53 (0.81%)

08:56
09/20/18
09/20
08:56
09/20/18
08:56
Recommendations
Carnival analyst commentary  »

William Blair continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COWN

Cowen Group

$15.55

0.2 (1.30%)

08:55
09/20/18
09/20
08:55
09/20/18
08:55
Conference/Events
Cowen Group management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Oct

BAC

Bank of America

$31.01

0.79 (2.61%)

, CRON

Cronos Group

$12.65

1.08 (9.33%)

08:55
09/20/18
09/20
08:55
09/20/18
08:55
Options
Notable open interest changes for September 20th »

Wednesday's total…

BAC

Bank of America

$31.01

0.79 (2.61%)

CRON

Cronos Group

$12.65

1.08 (9.33%)

GE

General Electric

$12.86

0.19 (1.50%)

FTV

Fortive

$85.99

-1.4 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

08:55
09/20/18
09/20
08:55
09/20/18
08:55
General news
FX Action: The dollar »

FX Action: The dollar was…

BLK

BlackRock

$483.50

11.365 (2.41%)

, CG

Carlyle Group

$23.45

-0.1 (-0.42%)

08:55
09/20/18
09/20
08:55
09/20/18
08:55
Conference/Events
Yahoo Finance to hold a summit »

All Markets Summit will…

BLK

BlackRock

$483.50

11.365 (2.41%)

CG

Carlyle Group

$23.45

-0.1 (-0.42%)

HD

Home Depot

$211.68

0.65 (0.31%)

Z

Zillow

$44.12

-0.49 (-1.10%)

BACHY

Bank of China

$0.00

(0.00%)

PYPL

PayPal

$89.31

-0.41 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 17

    Oct

  • 26

    Nov

NKE

Nike

$84.43

-0.86 (-1.01%)

08:53
09/20/18
09/20
08:53
09/20/18
08:53
Recommendations
Nike analyst commentary  »

Nike price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 25

    Sep

FLL

Full House Resorts

$2.83

(0.00%)

08:52
09/20/18
09/20
08:52
09/20/18
08:52
Initiation
Full House Resorts initiated  »

Full House Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COWN

Cowen Group

$15.55

0.2 (1.30%)

08:51
09/20/18
09/20
08:51
09/20/18
08:51
Conference/Events
Cowen Group management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Oct

CLAR

Clarus Corporation

$10.45

-0.35 (-3.24%)

08:50
09/20/18
09/20
08:50
09/20/18
08:50
Conference/Events
Clarus Corporation management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

08:50
09/20/18
09/20
08:50
09/20/18
08:50
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

ARKAY

Arkema

$0.00

(0.00%)

08:49
09/20/18
09/20
08:49
09/20/18
08:49
Conference/Events
Arkema management to meet with Morgan Stanley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

NKE

Nike

$84.43

-0.86 (-1.01%)

08:49
09/20/18
09/20
08:49
09/20/18
08:49
Recommendations
Nike analyst commentary  »

Nike price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 25

    Sep

ATIS

Attis Industries

$0.27

0.0075 (2.88%)

08:48
09/20/18
09/20
08:48
09/20/18
08:48
Conference/Events
Attis Industries to host business update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

OSB

Norbord

$36.13

-1.95 (-5.12%)

, MERC

Mercer

$16.50

-0.45 (-2.65%)

08:47
09/20/18
09/20
08:47
09/20/18
08:47
Conference/Events
TD Securities to hold a conference »

North American Forest…

OSB

Norbord

$36.13

-1.95 (-5.12%)

MERC

Mercer

$16.50

-0.45 (-2.65%)

CCDBF

CCL Industries

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 27

    Sep

GALT

Galectin Therapeutics

$6.07

0.07 (1.17%)

, AMPE

Ampio

$0.50

-0.0198 (-3.82%)

08:47
09/20/18
09/20
08:47
09/20/18
08:47
Periodicals
STAT's Feuerstein calls this morning's Galectin data meaningless' »

STAT's Adam…

GALT

Galectin Therapeutics

$6.07

0.07 (1.17%)

AMPE

Ampio

$0.50

-0.0198 (-3.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.